Insider Purchases: Inside the Buy
Tag: StocksToWatch
Can Freshpet Make for a Fresh Buy: Insiders & Directors Think So
Freshpet’s stock has tumbled more than 70% from its highs, but insiders keep buying and Wall Street funds are all-in (119% ownership!). With revenue growing, profitability improving, and valuation looking much more reasonable, is this the turnaround treat investors have been waiting for? 🐾🍖
Insiders Are Buying Shares of Applied Optoelectronics. Should You?
Applied Optoelectronics (AAOI) insiders—including the CEO—are buying big while revenue growth accelerates and losses shrink. Institutions already own two-thirds of the stock. But with dilution risk, short sellers circling, and heavy competition, is AAOI a comeback kid—or just another speculative fiber bet?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
COO Goes Shopping: Is Molina Healthcare (MOH) a Healthy Buy or Just a Check-Up?
When the COO of Molina Healthcare spends $1.56M on stock, investors notice. With Wall Street titans on board and shares at major support, is this a healthy buy — or a risky patient?
Proto Labs (PRLB): The CEO Bought Shares. Should You?
The CEO of Proto Labs just invested in his own company — but it’s not just him. Wall Street giants are in, revenue’s at record levels, and PRLB might be building toward a breakout. Should you 3D-print it into your portfolio?
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Can Elevance Reach Higher Elevations? The CEO Thinks So
📉 After falling nearly 50% from its highs, Elevance Health just got a $2.4M vote of confidence from its CEO. Is this the cure—or just another symptom? 🏥 Dive into the numbers, the risks, and the potential rewards. And yes, there will be icons. 📊💊📈
Healthpeak Properties (DOC): Insiders Are Buying—Should You?
📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.
PVH: Fashion. Fundamentals. CEO Buying. Doesn't the $500M Share Buyback Scream Deep Value?
CEO Stefan Larsson just bought $1M worth of PVH stock—and he’s not alone. With iconic brands like Calvin Klein and Tommy Hilfiger, institutional support over 100%, and a massive share buyback underway, PVH may be a classic turnaround play. But is it fashionably early… or just fashionably risky?